AromatherapyNCT07732036
Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement:
A study testing Inhalation Aromatherapy in people with Aromatherapy, run by Singapore General Hospital at 2 sites in Singapore.
Trial summary
The goal of this pilot clinical trial is to learn if inhalation aromatherapy works to reduce anxiety and pain in patients with venous leg ulcers undergoing conservative sharp wound debridement (CSWD). It will also learn about the feasibility of implementing this intervention in clinical practice. Read more about this study
- Who is it for?
- Ages 21 to 21 years
- Conditions the study is for
- Aromatherapy
- What is being tested?
- Inhalation Aromatherapy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 2 sitesSingapore
- Study dates
- 5 Jun 2026to 30 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 21 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- -≥21 years old
- -Venous leg ulcers requiring conservative sharp wound debridement
Who cannot join
- Known sensitivity or hypersensitivity to essential oils or any components in the Aromatherapy scent formulation
- Allergic rhinitis, asthma, chronic lung disease or any disease that impairs the sense of smell
- Airway hypersensitivity to fragrances, paint/gasoline fumes or turpentine
- Using aromatherapy of any kind
- Taking any anti-psychotic drugs
- Incapable of providing verbal/written consent
- On anti-anxiety medications
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore2 sites, 2 recruiting
- Recruiting
Singapore General Hospital
Singapore, Singapore
Singapore General Hospital Singapore General Hospital, 65762590 ext. +65, nurshing.research@sgh.com.sg
- Recruiting
Singapore General Hospital
Singapore, Singapore
Singapore General Hospital Singapore General Hospital, 65762590 ext. +65, nursing.research@sgh.com.sg
About this study
Official title: The Effectiveness and Acceptability of Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement: A Pilot Randomized Controlled Trial
The goal of this pilot clinical trial is to learn if inhalation aromatherapy works to reduce anxiety and pain in patients with venous leg ulcers undergoing conservative sharp wound debridement (CSWD). It will also learn about the feasibility of implementing this intervention in clinical practice. The main questions it aims to answer are:
Does inhalation aromatherapy reduce anxiety levels during CSWD procedures, as measured by STAI-S scores? Does inhalation aromatherapy reduce pain intensity during CSWD procedures? Is inhalation aromatherapy feasible and acceptable to implement in a clinical setting? What are the protocol adherence rates and potential areas of missing data?
Read more
Researchers will compare inhalation aromatherapy using Asian essential oil extracts to standard care to see if aromatherapy works to reduce anxiety and pain during wound debridement.
Participants will:
Receive either inhalation aromatherapy or standard care during their CSWD procedure Complete State-Trait Anxiety Inventory (STAI-S) questionnaires before and after the procedure Rate their pain intensity using visual analog scales during the debridement Provide feedback on treatment satisfaction and acceptability Attend clinic visits for wound debridement as part of their standard care
This pilot study hypothesizes that inhalation aromatherapy is feasible and acceptable to implement in a clinical setting and may be associated with differences in anxiety and pain intensity during CSWD, compared to standard care
- Conditions
- Aromatherapy
- Being tested
- Inhalation Aromatherapy
- Keywords
- Venous leg ulcers, Sharp wound debridement, Aromatherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inhalation AromatherapyOther
Patients are allocated to either the Inhalation Aromatherapy or Inhalation Placebo group in a 1:1 ratio via randomly permuted block randomization. The randomization sequence is generated by a non-study member using a computer-generated program. Allocation concealment is maintained through the use of sequentially numbered, opaque, sealed envelopes to prevent selection . Inhalation aromatherapy intervention an inhalation stick containing a blend of Asian aromatic plant extracts, including Basil, Elemi, and Calamansi, specifically selected for their pharmacological properties in alleviating anxiety, agitation, stress, and pain. Unlike conventional pharmacological interventions, the dose is not fixed but individually determined by the frequency of inhalation, varying based on individual pharmacokinetics and personal response to the aroma. Patients inhale at least twice, once in each nostril, beginning five minutes before the procedure and continuing throughout CSWD for up to ten minutes.
| Study group | Role | What they receive |
|---|---|---|
| Inhalation Aromatherapy- Intervention group | Experimental | Participants allocated to the intervention group receive a personal nasal inhalation stick infused with a blend of Asian aromatic plant extracts formulated by a qualified aromatherapist, selected based on known anxiolytic and analgesic pharmacological properties. The final blend is determined through a scent preference evaluation conducted with five VLU patient volunteers prior to the main study. Participants inhale the stick for 5 minutes before entering the clinic room and continue using it throughout the CSWD procedure for up to 10 minutes or until the procedure is completed, inhaling at least twice in each nostril prior to the procedure. Aromatherapy works through positive olfactory effects and direct modulation of the amygdala via the olfactory nerve, potentially reducing anxiety and enhancing comfort during the procedure. Each participant is issued their own inhalation stick for personal use across all study visits to maintain hygiene and ensure consistent dosing. Receives: Other: Inhalation Aromatherapy |
| Inhalation Placebo-Control group | Placebo comparator | Participants allocated to the control group receive a personal nasal inhalation stick identical in appearance, size, and packaging to the intervention stick, containing certified organic jojoba carrier oil with no known anxiolytic properties. Jojoba oil has a barely perceptible, slightly sweet aroma and is widely used in aromatherapy blends. Participants follow an identical inhalation protocol to the intervention group, inhaling for 5 minutes before the procedure and continuing throughout CSWD for up to 10 minutes or until the procedure is completed. This ensures that any non-specific effects of the inhalation ritual, including focused breathing and expectation of benefit, are equally present in both arms, thereby isolating the specific pharmacological effect of the aromatic compounds. Receives: Other: Inhalation Aromatherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participation Rate
The number of recruited patients divided by total eligible patients approached, expressed as a percentage.
Measured: Throughout the 12-month data collection period from October 2026 to September 2027.
Retention rate
The number of patients remaining divided by total patients who consented, expressed as a percentage.
Measured: The number of participants completed 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
Percentage Change in State Anxiety Level During Conservative Sharp Wound Debridement
Percentage change in STAI-S score at T1 (2nd clinic visit/2nd week/8th day): (pre-CSWD STAI-S minus post-CSWD STAI-S) divided by pre-CSWD STAI-S, multiplied by 100. Unit: percentage change on STAI-S scale. Percentage change in STAI-S score at T2 (3rd clinic visit/3rd week/15th Day), calculated.
Unit: percentage change on STAI-S scale. Reported separately to assess sustainability of effect over time.
Measured: Completed at 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3
Secondary outcomes (3)
Protocol Adherence Rate
Protocol adherence, which is given by the proportion of patients correctly receiving the allocated treatment out of all patients who consented to the study.
Measured: Assessed throughout the 12-month data collection period from October 2026 to September 2027.
Attrition Rate and Extent of Missing Data
Attrition rates (withdrawal or loss-to-follow-up as compared to completion of all 3 clinic visits)
Measured: Assessed through the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
Change in Pain Intensity During Conservative Sharp Wound Debridement
Change in pain intensity during CSWD, which is given by the difference in VAS score before and after CSWD
Measured: Change in pain intensity measured pre- and post-CSWD at T1 (2nd Clinic visit/8th Day) and T2 (3rd Clinic visit/15th Day) to assess sustainability, using (VAS), scored 0-100mm. Clinic visit 2 -8th Day- week 2, Clinic visit 3 -15th Day -week3.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2026
- Study start5 Jun 2026
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (22)Papers the sponsor has linked to this study.
- Other trials for AromatherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study employs a control trial design to evaluate the efficacy of inhalation aromatherapy in reducing procedural anxiety and pain during chronic wound debridement. Participants are randomized into either an intervention group receiving an inhalation stick containing a blend of Asian aromatic plant extracts, or a control group receiving an identical inhalation stick containing only jojoba carrier oil with no known anxiolytic properties. Both groups follow a standardized pain management plan, whereby patients consume their existing oral analgesic prior to the clinic visit. The intervention is administered for five minutes before the procedure and continued for up to ten minutes during the procedure. Feasibility and acceptability are assessed alongside primary outcomes, with acceptability measured via a five-point Likert scale satisfaction survey administered at the final visit.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Singapore General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07732036
- Sponsor's protocol ID
- ECOS Ref.: 2026-0326
- Other IDs
- AM/SU120/2026 (SRDUKAMR26S0)
- Status last verified
- Jul 2026
- First submitted
- 17 Jun 2026
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Rohi Ganji M, Jafari F, Rezaeian S, Abdi H, Farzaei MH, Khatony A. The Effect of Inhalation Aromatherapy and Music Therapy on Anxiety in Patients Undergoing Shockwave Lithotripsy: A Randomized Controlled Clinical Trial. Evid Based Complement Alternat Med. 2022 Jun 29;2022:8015798. doi: 10.1155/2022/8015798. eCollection 2022.
PubMed 35815287RETRACTION: The Role of Orthobiologics in Chronic Wound Healing. Int Wound J. 2025 Aug;22(8):e70744. doi: 10.1111/iwj.70744.
PubMed 40769517Liu YF, Ni PW, Huang Y, Xie T. Therapeutic strategies for chronic wound infection. Chin J Traumatol. 2022 Jan;25(1):11-16. doi: 10.1016/j.cjtee.2021.07.004. Epub 2021 Jul 6.
PubMed 34315658James KA, Stromin JI, Steenkamp N, Combrinck MI. Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. Front Endocrinol (Lausanne). 2023 Mar 6;14:1085950. doi: 10.3389/fendo.2023.1085950. eCollection 2023.
PubMed 36950689Thomas DC, Tsu CL, Nain RA, Arsat N, Fun SS, Sahid Nik Lah NA. The role of debridement in wound bed preparation in chronic wound: A narrative review. Ann Med Surg (Lond). 2021 Oct 4;71:102876. doi: 10.1016/j.amsu.2021.102876. eCollection 2021 Nov.
PubMed 34745599Cui J, Li M, Wei Y, Li H, He X, Yang Q, Li Z, Duan J, Wu Z, Chen Q, Chen B, Li G, Ming X, Xiong L, Qin D. Inhalation Aromatherapy via Brain-Targeted Nasal Delivery: Natural Volatiles or Essential Oils on Mood Disorders. Front Pharmacol. 2022 Apr 12;13:860043. doi: 10.3389/fphar.2022.860043. eCollection 2022.
PubMed 35496310Fiala CA, Abbott LI, Carter CD, Hillis SL, Wolf JS, Schuster M, Dulski R, Grice EA, Rakel BA, Gardner SE. Severe pain during wound care procedures: A cross-sectional study protocol. J Adv Nurs. 2018 May 7:10.1111/jan.13699. doi: 10.1111/jan.13699. Online ahead of print.
PubMed 29733454Matsuzaki K, Upton D. Wound treatment and pain management: a stressful time. Int Wound J. 2013 Dec;10(6):638-44. doi: 10.1111/j.1742-481X.2012.01038.x. Epub 2012 Aug 21.
PubMed 22905710Hedigan F, Sheridan H, Sasse A. Benefit of inhalation aromatherapy as a complementary treatment for stress and anxiety in a clinical setting - A systematic review. Complement Ther Clin Pract. 2023 Aug;52:101750. doi: 10.1016/j.ctcp.2023.101750. Epub 2023 Apr 5.
PubMed 37031643Zhang N, Yao L. Anxiolytic Effect of Essential Oils and Their Constituents: A Review. J Agric Food Chem. 2019 Dec 18;67(50):13790-13808. doi: 10.1021/acs.jafc.9b00433. Epub 2019 Jun 13.
PubMed 31148444Woo KY. Chronic wound-associated pain, psychological stress, and wound healing. Surg Technol Int. 2012 Dec;22:57-65.
PubMed 23023574Brown A. The assessment and treatment of wound pain. Nurs Times. 2015 Nov 18-24;111(47):15-7.
PubMed 26721090Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R. Slowing of wound healing by psychological stress. Lancet. 1995 Nov 4;346(8984):1194-6. doi: 10.1016/s0140-6736(95)92899-5.
PubMed 7475659McGuire L, Heffner K, Glaser R, Needleman B, Malarkey W, Dickinson S, Lemeshow S, Cook C, Muscarella P, Melvin WS, Ellison EC, Kiecolt-Glaser JK. Pain and wound healing in surgical patients. Ann Behav Med. 2006 Apr;31(2):165-72. doi: 10.1207/s15324796abm3102_8.
PubMed 16542131Briggs M, Nelson EA, Martyn-St James M. Topical agents or dressings for pain in venous leg ulcers. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD001177. doi: 10.1002/14651858.CD001177.pub3.
PubMed 23152206
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effectiveness and Acceptability of Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement: A Pilot Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07732036
- Acronym / sponsor ID
- ECOS Ref.: 2026-0326
- Conditions
- Aromatherapy
- Keywords
- Venous leg ulcers, Sharp wound debridement, Aromatherapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Singapore General HospitalUniversity, hospital or other
- Study start
- 5 Jun 2026 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Mar 2028 (estimated)
- First posted
- 28 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this pilot clinical trial is to learn if inhalation aromatherapy works to reduce anxiety and pain in patients with venous leg ulcers undergoing conservative sharp wound debridement (CSWD). It will also learn about the feasibility of implementing this intervention in clinical practice. The main questions it aims to answer are:
Does inhalation aromatherapy reduce anxiety levels during CSWD procedures, as measured by STAI-S scores? Does inhalation aromatherapy reduce pain intensity during CSWD procedures? Is inhalation aromatherapy feasible and acceptable to implement in a clinical setting? What are the protocol adherence rates and potential areas of missing data?
Researchers will compare inhalation aromatherapy using Asian essential oil extracts to standard care to see if aromatherapy works to reduce anxiety and pain during wound debridement.
Participants will:
Receive either inhalation aromatherapy or standard care during their CSWD procedure Complete State-Trait Anxiety Inventory (STAI-S) questionnaires before and after the procedure Rate their pain intensity using visual analog scales during the debridement Provide feedback on treatment satisfaction and acceptability Attend clinic visits for wound debridement as part of their standard care
This pilot study hypothesizes that inhalation aromatherapy is feasible and acceptable to implement in a clinical setting and may be associated with differences in anxiety and pain intensity during CSWD, compared to standard care
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This study employs a control trial design to evaluate the efficacy of inhalation aromatherapy in reducing procedural anxiety and pain during chronic wound debridement. Participants are randomized into either an intervention group receiving an inhalation stick containing a blend of Asian aromatic plant extracts, or a control group receiving an identical inhalation stick containing only jojoba carrier oil with no known anxiolytic properties. Both groups follow a standardized pain management plan, whereby patients consume their existing oral analgesic prior to the clinic visit. The intervention is administered for five minutes before the procedure and continued for up to ten minutes during the procedure. Feasibility and acceptability are assessed alongside primary outcomes, with acceptability measured via a five-point Likert scale satisfaction survey administered at the final visit.
| Arm | Type | Receives |
|---|---|---|
| Inhalation Aromatherapy- Intervention group | Experimental | Other: Inhalation AromatherapyParticipants allocated to the intervention group receive a personal nasal inhalation stick infused with a blend of Asian aromatic plant extracts formulated by a qualified aromatherapist, selected based on known anxiolytic and analgesic pharmacological properties. The final blend is determined through a scent preference evaluation conducted with five VLU patient volunteers prior to the main study. Participants inhale the stick for 5 minutes before entering the clinic room and continue using it throughout the CSWD procedure for up to 10 minutes or until the procedure is completed, inhaling at least twice in each nostril prior to the procedure. Aromatherapy works through positive olfactory effects and direct modulation of the amygdala via the olfactory nerve, potentially reducing anxiety and enhancing comfort during the procedure. Each participant is issued their own inhalation stick for personal use across all study visits to maintain hygiene and ensure consistent dosing. |
| Inhalation Placebo-Control group | Placebo comparator | Other: Inhalation AromatherapyParticipants allocated to the control group receive a personal nasal inhalation stick identical in appearance, size, and packaging to the intervention stick, containing certified organic jojoba carrier oil with no known anxiolytic properties. Jojoba oil has a barely perceptible, slightly sweet aroma and is widely used in aromatherapy blends. Participants follow an identical inhalation protocol to the intervention group, inhaling for 5 minutes before the procedure and continuing throughout CSWD for up to 10 minutes or until the procedure is completed. This ensures that any non-specific effects of the inhalation ritual, including focused breathing and expectation of benefit, are equally present in both arms, thereby isolating the specific pharmacological effect of the aromatic compounds. |
Who may qualify
- Ages
- 21 to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- -≥21 years old
- -Venous leg ulcers requiring conservative sharp wound debridement
Key exclusion criteria (7 listed)
- Known sensitivity or hypersensitivity to essential oils or any components in the Aromatherapy scent formulation
- Allergic rhinitis, asthma, chronic lung disease or any disease that impairs the sense of smell
- Airway hypersensitivity to fragrances, paint/gasoline fumes or turpentine
- Using aromatherapy of any kind
- Taking any anti-psychotic drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inhalation AromatherapyPatients are allocated to either the Inhalation Aromatherapy or Inhalation Placebo group in a 1:1 ratio via randomly permuted block randomization. The randomization sequence is generated by a non-study member using a computer-generated program. Allocation concealment is maintained through the use of sequentially numbered, opaque, sealed envelopes to prevent selection . Inhalation aromatherapy intervention an inhalation stick containing a blend of Asian aromatic plant extracts, including Basil, Elemi, and Calamansi, specifically selected for their pharmacological properties in alleviating anxiety, agitation, stress, and pain. Unlike conventional pharmacological interventions, the dose is not fixed but individually determined by the frequency of inhalation, varying based on individual pharmacokinetics and personal response to the aroma. Patients inhale at least twice, once in each nostril, beginning five minutes before the procedure and continuing throughout CSWD for up to ten minutes. | Other | Inhalation Aromatherapy- Intervention group, Inhalation Placebo-Control group |
Primary outcome
Participation Rate
Time frame: Throughout the 12-month data collection period from October 2026 to September 2027.
The number of recruited patients divided by total eligible patients approached, expressed as a percentage.
Retention rate
Time frame: The number of participants completed 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
The number of patients remaining divided by total patients who consented, expressed as a percentage.
Percentage Change in State Anxiety Level During Conservative Sharp Wound Debridement
Time frame: Completed at 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3
Percentage change in STAI-S score at T1 (2nd clinic visit/2nd week/8th day): (pre-CSWD STAI-S minus post-CSWD STAI-S) divided by pre-CSWD STAI-S, multiplied by 100. Unit: percentage change on STAI-S scale. Percentage change in STAI-S score at T2 (3rd clinic visit/3rd week/15th Day), calculated. Unit: percentage change on STAI-S scale. Reported separately to assess sustainability of effect over time.
3 secondary outcomes
Protocol Adherence Rate
Time frame: Assessed throughout the 12-month data collection period from October 2026 to September 2027.
Attrition Rate and Extent of Missing Data
Time frame: Assessed through the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
Change in Pain Intensity During Conservative Sharp Wound Debridement
Time frame: Change in pain intensity measured pre- and post-CSWD at T1 (2nd Clinic visit/8th Day) and T2 (3rd Clinic visit/15th Day) to assess sustainability, using (VAS), scored 0-100mm. Clinic visit 2 -8th Day- week 2, Clinic visit 3 -15th Day -week3.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Background: PubMed 35815287Rohi Ganji M, Jafari F, Rezaeian S, Abdi H, Farzaei MH, Khatony A. The Effect of Inhalation Aromatherapy and Music Therapy on Anxiety in Patients Undergoing Shockwave Lithotripsy: A Randomized Controlled Clinical Trial. Evid Based Complement Alternat Med. 2022 Jun 29;2022:8015798. doi: 10.1155/2022/8015798. eCollection 2022.
- Background: PubMed 40769517RETRACTION: The Role of Orthobiologics in Chronic Wound Healing. Int Wound J. 2025 Aug;22(8):e70744. doi: 10.1111/iwj.70744.
- Background: PubMed 34315658Liu YF, Ni PW, Huang Y, Xie T. Therapeutic strategies for chronic wound infection. Chin J Traumatol. 2022 Jan;25(1):11-16. doi: 10.1016/j.cjtee.2021.07.004. Epub 2021 Jul 6.
- Background: PubMed 36950689James KA, Stromin JI, Steenkamp N, Combrinck MI. Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. Front Endocrinol (Lausanne). 2023 Mar 6;14:1085950. doi: 10.3389/fendo.2023.1085950. eCollection 2023.
- Background: PubMed 34745599Thomas DC, Tsu CL, Nain RA, Arsat N, Fun SS, Sahid Nik Lah NA. The role of debridement in wound bed preparation in chronic wound: A narrative review. Ann Med Surg (Lond). 2021 Oct 4;71:102876. doi: 10.1016/j.amsu.2021.102876. eCollection 2021 Nov.
- Background: PubMed 35496310Cui J, Li M, Wei Y, Li H, He X, Yang Q, Li Z, Duan J, Wu Z, Chen Q, Chen B, Li G, Ming X, Xiong L, Qin D. Inhalation Aromatherapy via Brain-Targeted Nasal Delivery: Natural Volatiles or Essential Oils on Mood Disorders. Front Pharmacol. 2022 Apr 12;13:860043. doi: 10.3389/fphar.2022.860043. eCollection 2022.
- Background: PubMed 29733454Fiala CA, Abbott LI, Carter CD, Hillis SL, Wolf JS, Schuster M, Dulski R, Grice EA, Rakel BA, Gardner SE. Severe pain during wound care procedures: A cross-sectional study protocol. J Adv Nurs. 2018 May 7:10.1111/jan.13699. doi: 10.1111/jan.13699. Online ahead of print.
- Background: PubMed 22905710Matsuzaki K, Upton D. Wound treatment and pain management: a stressful time. Int Wound J. 2013 Dec;10(6):638-44. doi: 10.1111/j.1742-481X.2012.01038.x. Epub 2012 Aug 21.
- Background: PubMed 37031643Hedigan F, Sheridan H, Sasse A. Benefit of inhalation aromatherapy as a complementary treatment for stress and anxiety in a clinical setting - A systematic review. Complement Ther Clin Pract. 2023 Aug;52:101750. doi: 10.1016/j.ctcp.2023.101750. Epub 2023 Apr 5.
- Background: PubMed 31148444Zhang N, Yao L. Anxiolytic Effect of Essential Oils and Their Constituents: A Review. J Agric Food Chem. 2019 Dec 18;67(50):13790-13808. doi: 10.1021/acs.jafc.9b00433. Epub 2019 Jun 13.
- Background: PubMed 23023574Woo KY. Chronic wound-associated pain, psychological stress, and wound healing. Surg Technol Int. 2012 Dec;22:57-65.
- Background: PubMed 26721090Brown A. The assessment and treatment of wound pain. Nurs Times. 2015 Nov 18-24;111(47):15-7.
Related trials for Aromatherapy
Recruiting
The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With Pneumonia
Pneumonia, Dyspnea
Recruiting
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Recruiting
Rehabilitation of Taste and Smell Disorders Associated With Chemotherapy Using Aromatherapy
Cancer
Active, not recruiting
Deep Breathing Relaxation and Lemongrass Aromatherapy on Pain
Chronic Kidney Disease; End-Stage Renal Disease; Hemodialysis; Pain; Anxiety
Enrolling by invitation
The Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients
Fibromyalgia, Aromatherapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Inhalation Aromatherapy in people with Aromatherapy, run by Singapore General Hospital at 2 sites in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nanthakumahrie Gunasegaran (97250435 ext. +65, nanthakumahrie.gunasegaran@sgh.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participation Rate (time frame: Throughout the 12-month data collection period from October 2026 to September 2027.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07732036, which also lists 22 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.